(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 July 2006 (20.07.2006)

PCT

(10) International Publication Number
WO 2006/076593 A1

(51) International Patent Classification:
C07D 401/06 (2006.01) *A61P 35/04* (2006.01)
A61K 31/404 (2006.01)

(21) International Application Number:
PCT/US2006/001272

(22) International Filing Date: 13 January 2006 (13.01.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/643,886 14 January 2005 (14.01.2005) US
60/732,999 2 November 2005 (02.11.2005) US

(71) Applicant *(for all designated States except US)*: **CGI PHARMACEUTICALS, INC.** [US/US]; 36 East Industrial Road, Branford, Connecticut 06405 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MITCHELL, Scott A.** [US/US]; 13 Morris Road, East Haven, Connecticut 06513 (US). **DANCA, Mihaela Diana** [US/US]; 13 Corey Lane, Mendham, New Jersey 07945 (US). **BLOMGREN, Peter A.** [US/US]; 20 James Road, North Branford, Connecticut 06471 (US). **DESIMONE, Robert W.** [US/US]; 37 Gina Drive, Durham, Connecticut 06422 (US). **PIPPIN, Douglas A. I.** [US/US]; 6 Phillips Lane, Chester Springs, Pennsylvania 19425 (US). **BRITTELLI, David R.** [US/US]; 240 Stony Creek Road, Branford, Connecticut 06405 (US).

(74) Agent: **STEVENS, Lauren L.**; Finnegan, Henderson, Farabow, Garrett & Dunner LLP, 901 New York Avenue, Washington, D.C., District Of Columbia 20001-4413 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY



(1)

(57) Abstract: Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are also provided herein. Use in treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck sguamous cell carcinoma. A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with at least one chemical entity under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom

WO 2006/076593 A1